Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
National survey finds a majority of people with HBV or HCV don’t know their status.
Hep B vaccines have been around for 35 years now, but a majority of people at risk are not protected.
Conatus Pharmaceuticals’ study of emricasan for non-alcoholic steatohepatitis found the drug had no significant impact.
Study finds people who took daily aspirin had a lower risk of NASH and advanced liver scarring.
Researchers found that this association was statistically significant beginning five years after treatment.
Researchers analyzed health data regarding modern hep C treatments specific to New South Wales.
CDC experts recommend the vaccine for children, teens and HIV-positive people.
Researchers reached this conclusion after reviewing data on more than 30,000 people.
European and U.S. guidelines recommend that all those with cirrhosis undergo biannual screening for liver cancer.
Phase III study misses statistical threshold, but the immunotherapy appears to show some benefit.
Researchers have identified the pathways by which hepatitis C suppresses the natural immune response to its presence.
Researchers argue that the distinctions between the two conditions are quite blurred.
Study in China sees an association with several cancer types, especially gastrointestinal malignancies.
A meta-analysis has helped clear up conflicting previous evidence regarding this association.
A study of gay and bi men with HIV in Australia who had been cured of hep C found they associated hep C with injection drug use.
Such a model is greatly needed for research into a hepatitis C vaccine.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.